Natco Pharma, Alvogen file ANDA for Ibrutinib tablets for US markets

The company further believes that ANDA may be eligible for 180 days of marketing exclusivity at the time of potential launch of the product under certain circumstances, as per BSE filing.

from India Infoline News Service http://bit.ly/2WoT0z4